



April 15, 2019

Novartis Pharma AG  
CH-4002, Basel, Switzerland

Reference: EudraCT 2006-006803-35/ Novartis Protocol ID CABF656A2201

A multiple-dose, double-blind, placebo-controlled, parallel study to assess the efficacy, safety and tolerability of ACZ885 (Canikumab) in patients with pulmonary sarcoidosis

Trial CABF656A2201 was cancelled with no patient enrollment and as such, no results will be reported.